ALUMINUM DETERMINATION IN THE SKIN OF PATIENTS WITH AND WITHOUT END-STAGE RENAL-FAILURE

被引:2
|
作者
SUBRA, JF [1 ]
KRARI, N [1 ]
TIROT, P [1 ]
MAURAS, Y [1 ]
BALIT, G [1 ]
VANWEYDEVELT, FC [1 ]
ALLAIN, P [1 ]
机构
[1] CTR HOSP REG & UNIV ANGERS, PHARMACOL LAB, F-49033 ANGERS, FRANCE
关键词
ALUMINUM; SKIN; SERUM; DEFEROXAMINE INFUSION TEST; HEMODIALYSIS; RENAL FAILURE;
D O I
10.1159/000186409
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aluminium (Al) concentration in the skin was determined by inductively coupled plasma optical emission spectrometry to look for a correlation between Al exposure and skin content in patients with end-stage renal failure. Skin Al concentrations were higher in dialyzed patients than in the nondialyzed group (1.02 +/- 0.30 vs. 0.26 +/- 0.10-mu-g/g; p < 0.001). Moreover, in the dialyzed group, the patients treated for more than 100 months had a higher concentration of Al in the skin than the others (1.20 +/- 0.26 vs. 0.80 +/- 0.18-mu-g/g; p < 0.05). Al skin content correlated better with the deferoxamine infusion test (DIT) than with Al blood plasma concentration. In conclusion, our data confirm that the DIT is a valuable tool for the evaluation of body Al content.
引用
收藏
页码:170 / 173
页数:4
相关论文
共 50 条
  • [21] HEMODIALYSIS CLEARANCE OF ETHOSUXIMIDE IN END-STAGE RENAL-FAILURE PATIENTS
    MARBURY, TC
    LEE, CS
    PERCHALSKI, RJ
    WANG, LH
    WILDER, BJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 264 - 264
  • [22] SELECTION OF PATIENTS FOR END-STAGE RENAL-FAILURE TREATMENT - IS IT POSSIBLE
    HERNANDO, L
    NEFROLOGIA, 1994, 14 : 20 - 23
  • [23] TREATMENT OF HYPERCALCEMIA WITH PAMIDRONATE IN PATIENTS WITH END-STAGE RENAL-FAILURE
    DAVENPORT, A
    GOEL, S
    MACKENZIE, JC
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1993, 27 (04): : 447 - 451
  • [24] VESICOURETERAL REFLUX IN PATIENTS IN END-STAGE CHRONIC RENAL-FAILURE
    MOSCONI, CEV
    IANHEZ, LE
    BORRELLI, M
    SABBAGA, E
    FREIRE, JGC
    UROLOGIA INTERNATIONALIS, 1975, 30 (05) : 357 - 361
  • [25] QUALITY-OF-LIFE FOR PATIENTS WITH END-STAGE RENAL-FAILURE
    FOX, E
    PEACE, K
    NEALE, TJ
    MORRISON, RBI
    HATFIELD, PJ
    MELLSOP, G
    RENAL FAILURE, 1991, 13 (01) : 31 - 35
  • [26] CARDIOVASCULAR-DISEASE IN PATIENTS WITH END-STAGE RENAL-FAILURE
    GREAVES, SC
    SHARPE, DN
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1992, 22 (02): : 153 - 159
  • [27] PHARMACOKINETICS OF INTRAVENOUS VANCOMYCIN IN PATIENTS WITH END-STAGE RENAL-FAILURE
    TAN, CC
    LEE, HS
    TI, TY
    LEE, EJC
    THERAPEUTIC DRUG MONITORING, 1990, 12 (01) : 29 - 34
  • [28] MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH END-STAGE RENAL-FAILURE
    PORT, FK
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (03) : 215 - 217
  • [29] PERCUTANEOUS RENAL BIOPSY IN END-STAGE RENAL-FAILURE
    RAKOWSKI, TA
    ARGY, WP
    CURTIS, JJ
    SCHREINER, GE
    CLINICAL RESEARCH, 1975, 23 (01): : A37 - A37
  • [30] PSYCHOSOMATIC ASPECTS OF END-STAGE RENAL-FAILURE
    SENSKY, T
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 1993, 59 (02) : 56 - 68